Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read it and you will get a good understanding
MHO, solution sales is the driver here. The Instrument that develops the solution is more than likely (JITD) Just In Time Delivery. It make more sense to do this than to stock pile and pay Manufacturing cost upfront before it is sold.
The Plant can make runs of solution as needed as well (JITD), it has a short shelf life and has to gain access to sites right now. That is why you see the company hire new workers, that is because solution sales at manufacturer is in a parabolic state, with an insuing rapid downturn once we cross the peak of COVID.
At such time, the instrument that develops the solution will then began to arrive at said locations that purchased solutions during the peak of COVID.
Sales of units are picking up rapidly as well, but also keep in mind logistics and Manufacturing capabilities during COVID. High Priority are Drugs, VENTS, Food, and other instruments needed to combat COVID.
Ground shipment from Manufacturer of instruments from PCTL direct to purchaser is critical.
(BLUF) Sales of solution will be very significant, the Instruments FUTURES are also very significant. I suspect this coming week we will see sales reports of SOLUTIONS first, with follow along trailing data sales of instruments, throughout the US and Global.
Is it a fare price target of $34 PPS? IMHO Yes, the question is time to horizon of said price and performance of shorts. I plan to hold through COVID 100% of shares I currently have.
Could very well be a target for the Big Guys to snatch-up as well, and then you will certainly see that $34 PPS Target hit overnight.
The risk of missing a huge moves is not worth the flip.
MHO, solution sales is the driver here. The Instrument that develops the solution is more than likely (JITD) Just In Time Delivery. It make more sense to do this than to stock pile and pay Manufacturing cost upfront before it is sold.
The Plant can make runs of solution as needed as well (JITD), it has a short shelf life and has to gain access to sites right now. That is why you see the company hire new workers, that is because solution sales at manufacturer is in a parabolic state, with an insuing rapid downturn once we cross the peak of COVID.
At such time, the instrument that develops the solution will then began to arrive at said locations that purchased solutions during the peak of COVID.
Sales of units are picking up rapidly as well, but also keep in mind logistics and Manufacturing capabilities during COVID. High Priority are Drugs, VENTS, Food, and other instruments needed to combat COVID.
Ground shipment from Manufacturer of instruments from PCTL direct to purchaser is critical.
(BLUF) Sales of solution will be very significant, the Instruments FUTURES are also very significant. I suspect this coming week we will see sales reports of SOLUTIONS first, with follow along trailing data sales of instruments, throughout the US and Global.
Is it a fare price target of $34 PPS? IMHO Yes, the question is time to horizon of said price and performance of shorts. I plan to hold through COVID 100% of shares I currently have.
Could very well be a target for the Big Guys to snatch-up as well, and then you will certainly see that $34 PPS Target hit overnight.
The risk of missing a huge moves is not worth the flip.
Get left in the dust quick
Don't get caught with your boxers down
I keep saying buyout LOL
.50 this coming week.
Reputable source, look it up online bud.
I agree, but very well much sooner than EOY we will see 3 PPS.
IMHO, solution sales is the driver here. The Instrument that develops the solution is more than likely (JITD) Just In Time Delivery. It make more sense to do this than to stock pile and pay Manufacturing cost upfront before it is sold.
The Plant can make runs of solution as needed as well (JITD), it has a short shelf life and has to gain access to sites right now. That is why you see the company hire new workers, that is because solution sales at manufacturer is in a parabolic state, with an insuing rapid downturn once we cross the peak of COVID.
At such time, the instrument that develops the solution will then began to arrive at said locations that purchased solutions during the peak of COVID.
Sales of units are picking up rapidly as well, but also keep in mind logistics and Manufacturing capabilities during COVID. High Priority are Drugs, VENTS, Food, and other instruments needed to combat COVID.
Ground shipment from Manufacturer of instruments from PCTL direct to purchaser is critical.
(BLUF) Sales of solution will be very significant, the Instruments FUTURES are also very significant. I suspect this coming week we will see sales reports of SOLUTIONS first, with follow along trailing data sales of instruments, throughout the US and Global.
Is it a fare price target of $34 PPS? IMHO Yes, the question is time to horizon of said price and performance of shorts. I plan to hold through COVID 100% of shares I currently have.
Could very well be a target for the Big Guys to snatch-up as well, and then you will certainly see that $34 PPS Target hit overnight.
The risk of missing a huge moves is not worth the flip.
Folks sold to fast
That's for sure
Loaded on dips today, gotta reload my guns and shoot some more next week.
WHEN Q HITS, O CHIT.
They are going to swallow it whole for a cheap price of 5-10 Bucks PPS
Gulp says a Big Pharm CO to Akor
IMHO PPS BUYOUT $5 to $10 PPS at close on monday
I think they have a buyer
Akorn Provides Fourth Quarter and Full Year 2019 Results
LAKE FOREST, Ill., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2019.
Fourth Quarter 2019 Results and Recent Developments
Net revenue was $162 million, an increase of $9 million, or 5.8%, compared to the fourth quarter of 2018.
Net loss was $81 million compared to a net loss of $215 million in the fourth quarter of 2018.
Adjusted EBITDA was $18 million compared to $(20) million in the fourth quarter of 2018.
Reached an agreement with our lenders to execute a sale of Akorn’s business, potentially using Chapter 11 protection, as previously disclosed on the Company’s Form 8-K filed on February 12, 2020.
Its coming for sure
Waiting on huge news at this point
Yea, I am shocked stupids selling
Wait 90 days and make a mil
Chit, 35 dollar PPS I see why.
Crazy as chit to sell at this level, knowing full well whats coming.
Loading at these levels
Dollar today, just my honest opinion
Time for second climb
It hit 200 day low 2 days ago, started tracking and loading at that time.
IMHO 10 bucs on the horizon
Awesome big guy
The Pump dog dont hunt here, this is the real deal.
Geeees, super hot OTC Stock.
Wait til Q's come out OMG this is gonna be HUGGGGGEEEE
I keep seeing $35 PPS Why and How???
I smell a buyout, gonna load like hell on this one.
Lets see if this thing climbs back in the saddle.
Would someone by this POS company for 2 bucs a share, would be happy lol
Maybe it could still gap up if they put out some more crazy speculative news
I only put 700 bucks on this POS and still pissed off